Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06629584 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
A Phase 2 study of Malignant Solid Tumors, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06629584 is a Phase 2 study of Malignant Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 3,381-participant average among 3 other Malignant Solid Tumors trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06629584, a Phase 2 study of Malignant Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
Conditions Studied
Interventions
- DRUG Asciminib
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-02-14 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06629584
The ClinicalTrials.gov registry entry for NCT06629584 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,381-participant average among 3 other Malignant Solid Tumors trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Asciminib is the first listed.
NCT06629584 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06629584 about?
NCT06629584 is a clinical study titled "Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia". This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.
What is the current status of trial NCT06629584?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-02-14. Estimated completion is 2028-12-31.
What conditions does trial NCT06629584 study?
This clinical trial studies the following conditions: Malignant Solid Tumors.
What interventions are being tested in trial NCT06629584?
The interventions under investigation include: Asciminib (DRUG).
Who is sponsoring clinical trial NCT06629584?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06629584 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.